X
LIVE

Serial Number

97539827

Owner

Elsie Biotechnologies Inc.

Attorney

Christopher M. Hanes

Filing Date

Aug 8, 2022

Add to watchlist:

No watchlists yet
View on USPTO

X Trademark

Serial Number: 97539827

X is a trademark filed by Elsie Biotechnologies Inc. on August 8, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Elsie Biotechnologies Inc. (2 trademarks)

10355 Science Center Drive, Suite 110
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

August 8, 2022

Registration Date

Not Registered

Published for Opposition

September 19, 2023

Goods & Services

Research and development of oligonucleotide compounds for use in pharmaceutical therapies; Research and development of oligonucleotide delivery agents for use in pharmaceutical therapies; Research and development of oligonucleotide-based or -derived pharmaceuticals; Research and development of pharmaceuticals comprised of oligonucleotide compounds; Research and development of oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Research and development of drug delivery agents consisting of oligonucleotide compounds

Oligonucleotide compounds for use as pharmaceutical therapies for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents that facilitate delivery of a wide range of pharmaceutical therapies; Oligonucleotide-based or -derived pharmaceuticals for the treatment of a wide variety of conditions and illnesses; Pharmaceuticals comprised of oligonucleotide compounds for the treatment of a wide variety of conditions and illnesses ; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals

Oligonucleotide compounds for use in the manufacture of pharmaceutical therapies

Custom manufacture of oligonucleotides

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 24, 2025 EXRA
SOU EXTENSION 4 GRANTED
Oct 23, 2025 EX4G
SOU EXTENSION 4 FILED
Oct 23, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
May 2, 2025 EX3G
SOU EXTENSION 3 FILED
May 2, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
May 2, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 18, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 18, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 18, 2024 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 11, 2024 EXRA
SOU EXTENSION 2 GRANTED
Dec 11, 2024 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 9, 2024 AITU
SOU EXTENSION 2 FILED
Nov 12, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 12, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 1, 2024 EXRA
SOU EXTENSION 1 GRANTED
Apr 30, 2024 EX1G
SOU EXTENSION 1 FILED
Apr 30, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 30, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 14, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 30, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 2, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 2, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 16, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 16, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 16, 2023 CNRT
ASSIGNED TO EXAMINER
May 24, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 30, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 29, 2022 NWOS
NEW APPLICATION ENTERED
Aug 11, 2022 NWAP